Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GLOBAL Regulatory Writing & Consulting | Contract Pharma

What are you searching for?

Sign in

Search by

GLOBAL Regulatory Writing & Consulting

Company Headquarters

14900 Interurban Avenue South, Suite 271, PMB 98, Seattle, WA, 98168, US

Driving Directions Phone: View Phone
View website

Request more information from GLOBAL Regulatory Writing & Consulting

Request more information from GLOBAL Regulatory Writing & Consulting

Categories from GLOBAL Regulatory Writing & Consulting

505(b)(2)
Auditing
Biologics Process Development
Biosimilars
CMC (Chemistry, Manfacturing & Controls)
Consulting
Consulting, Audits & Inspections
Consulting, Process Analytical Technology (PAT)
Consulting, Process Excellence
Consulting, Quality Management Systems
Consulting, Records Management
Consulting, Regulatory
Custom Protocols
DMF Establishment / Maintenance
Documentation Support Services
GMP Auditing
IND/NDA Submissions
Project Management
QA/QC
Regulatory Affairs Consultants
Training

Related Content

Collaborations & Alliances

ProBio, Kun Tuo Partner to Accelerate Advancement of Innovative Therapies in China

The two companies will provide integrated support across CMC, non-clinical studies, and clinical operations.

By: Patrick Lavery

Trials & Filings

T-Maximum Gains FDA Fast Track Status for CAR-T Glioblastoma Therapy

MT027 previously received Orphan Drug Designation, and T-Maximum was authorized to start a Phase II study.

By: Patrick Lavery

Breaking News

PTC to Acquire Sangamo’s Fabry Disease Gene Therapy

ST-920 is a one-time administered AAV gene therapy undergoing BLA review for Fabry disease.

By: Charlie Sternberg

Promotions & Moves

ILiAD Appoints Former GSK Exec as Chief Business Officer

Antony Blanc is a seasoned biopharmaceutical executive with experience in corporate strategy, vaccine development and commercialization, business development and partnering.

By: Charlie Sternberg

Collaborations & Alliances

Mediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases

These diseases are characterized by myofibroblast activation, scarring, inflammation, and tissue remodeling, and can lead to organ failure.

By: Patrick Lavery

White Papers / Tech Papers

Navigating the BLA Pathway: A Guide to Analytical Characterization of Complex Molecular Formats

Lonza's new white paper shows how modern analytics — from MAM to automated glycan analysis — turn complex biologics characterization into a competitive advantage.

Released By Lonza

Collaborations & Alliances

Catalent, Nanoscope Expand MCO-010 Gene Therapy Partnership

Catalent will support commercial packaging and distribution as Nanoscope advances its rolling BLA submission.

By: Charlie Sternberg

Breaking News

Single Use Support Unveils RoSS.BLST Next-Gen Blast Freezer

The freezing and thawing platform is designed for maximizing process consistency and product quality for high-value biologics.

By: Patrick Lavery

Thermo Fisher Scientific

Pharma Matters Q&A

Dynamics Reshaping Expectations for CMC Strategy and Execution

As development programs become more complex, sponsors increasingly benefit from a coordinated approach that connects clinical strategy, CMC, manufacturing, and supply planning.

Released By Thermo Fisher Scientific Pharma Services

Trials & Filings

AstraZeneca’s Imfinzi Approved by FDA for BCG-Naïve Non-Muscle-Invasive Bladder Cancer

This marks the latest indication in oncology for Imfinzi nine years after the drug’s first approval.

By: Patrick Lavery

Trials & Filings

Valar Labs Gets FDA Breakthrough Device Nod for Vesta Bladder Cancer Risk Test

Vesta Bladder Risk Stratify Dx becomes the first AI-powered digital pathology prognostic test in bladder cancer to receive the designation.

By: Patrick Lavery

Collaborations & Alliances

Blackstone Life Sciences Invests $250M in Anagram Therapeutics for Pancreatic Enzyme Replacement Therapy

Namely, the investment helps fund further development, approval, and launch of Anagram’s ANG003.

By: Patrick Lavery

Promotions & Moves

Oryon Cell Therapies Appoints Dr. Burkhard Blank as Chief Medical Officer

The veteran drug development leader brings extensive global experience.

By: Charlie Sternberg

Breaking News

Kincell Bio Expands Research Triangle Park, North Carolina Facility

New infrastructure aims to support clients as they advance from late-stage clinical CMC development through commercialization and post-approval life cycle management.

By: Charlie Sternberg

Features

Check for Yourself: How to Effectively Contact CMC CDMO References

Practical guidance for sponsors to extract meaningful insight—and avoid costly surprises— when vetting CDMO partners.

By: Michael Spangler, Tobi Williams